NAGE Q4 2021 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+15.0% YoY

Gross Profit

$11M61.2% margin

Operating Income

-$5M-29.9% margin

Net Income

-$5M-30.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$58M

Total Liabilities

$26M

Stockholders' Equity

$32M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$15M	+15.0%
Gross Profit	$11M	$9M	+15.4%
Operating Income	-$5M	-$6M	+12.6%
Net Income	-$5M	-$6M	+12.7%